MX370408B - Sal de compuesto heterociclico sustituido con halogeno. - Google Patents
Sal de compuesto heterociclico sustituido con halogeno.Info
- Publication number
- MX370408B MX370408B MX2016017371A MX2016017371A MX370408B MX 370408 B MX370408 B MX 370408B MX 2016017371 A MX2016017371 A MX 2016017371A MX 2016017371 A MX2016017371 A MX 2016017371A MX 370408 B MX370408 B MX 370408B
- Authority
- MX
- Mexico
- Prior art keywords
- halogen
- salt
- heterocyclic compound
- substituted heterocyclic
- alkali
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 3
- 229910052783 alkali metal Inorganic materials 0.000 abstract 2
- 150000001340 alkali metals Chemical class 0.000 abstract 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 abstract 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Divinylene sulfide Natural products C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 abstract 1
- 102000004137 Lysophosphatidic Acid Receptors Human genes 0.000 abstract 1
- 108090000642 Lysophosphatidic Acid Receptors Proteins 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
- 229930192474 thiophene Natural products 0.000 abstract 1
- -1 thiophene compound Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/36—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Abstract
La invención proporciona una sal del compuesto novedoso de tiofeno sustituido con a-halógeno que tiene una acción antagonista potente del receptor de LPA y es útil como un medicamento; la sal se representada por la fórmula general (I): (ver Fórmula) (en donde R es un átomo de hidrógeno o un grupo metoxi; X es un átomo de halógeno; A se selecciona del grupo que consiste de: (ver Fórmula) M es un metal alcalino o un metal alcalinotérreo; y n es 1 cuando M es un metal alcalino y es 2 cuando M es un metal alcalinotérreo).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014132413 | 2014-06-27 | ||
| PCT/JP2015/068575 WO2015199234A1 (ja) | 2014-06-27 | 2015-06-26 | ハロゲン置換へテロ環化合物の塩 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016017371A MX2016017371A (es) | 2017-05-01 |
| MX370408B true MX370408B (es) | 2019-12-11 |
Family
ID=54938311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016017371A MX370408B (es) | 2014-06-27 | 2015-06-26 | Sal de compuesto heterociclico sustituido con halogeno. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10023554B2 (es) |
| EP (1) | EP3162801B1 (es) |
| JP (1) | JP6579103B2 (es) |
| KR (1) | KR102433588B1 (es) |
| CN (1) | CN106458964B (es) |
| AU (1) | AU2015281021B9 (es) |
| CA (1) | CA2953472C (es) |
| ES (1) | ES2824801T3 (es) |
| MX (1) | MX370408B (es) |
| RU (1) | RU2689315C2 (es) |
| WO (1) | WO2015199234A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10000459B2 (en) | 2013-03-15 | 2018-06-19 | Epigen Biosciences, Inc. | Heterocyclic compounds useful in the treatment of disease |
| WO2017086430A1 (ja) * | 2015-11-20 | 2017-05-26 | 宇部興産株式会社 | Ｎａｓｈの治療又は予防のための医薬組成物 |
| CN114206832A (zh) * | 2019-07-30 | 2022-03-18 | 大正制药株式会社 | 拮抗lpa1受体的脲化合物 |
| KR20220101137A (ko) | 2019-11-15 | 2022-07-19 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제로서의 트라이아졸 카르바메이트 피리딜 설폰아미드 및 이의 용도 |
| CA3185689A1 (en) | 2020-06-03 | 2021-12-09 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| TWI838626B (zh) | 2020-06-03 | 2024-04-11 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| KR20240005892A (ko) | 2021-05-11 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제 및 이의 용도 |
| AU2022405082A1 (en) | 2021-12-08 | 2024-07-11 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001060819A1 (fr) * | 2000-02-18 | 2001-08-23 | Kirin Beer Kabushiki Kaisha | Nouveaux composes d'isoxazole et de thiazole et leur utilisation en tant que medicaments |
| DE60234318D1 (de) | 2001-02-08 | 2009-12-24 | Ono Pharmaceutical Co | Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors |
| JP4692281B2 (ja) | 2003-08-05 | 2011-06-01 | 味の素株式会社 | 新規アゾール化合物 |
| GB2466121B (en) | 2008-12-15 | 2010-12-08 | Amira Pharmaceuticals Inc | Antagonists of lysophosphatidic acid receptors |
| GB2470833B (en) | 2009-06-03 | 2011-06-01 | Amira Pharmaceuticals Inc | Polycyclic antagonists of lysophosphatidic acid receptors |
| CN102574822A (zh) | 2009-08-04 | 2012-07-11 | 阿米拉制药公司 | 作为溶血磷脂酸受体拮抗剂的化合物 |
| GB2474748B (en) | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
| GB2474120B (en) | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
| WO2011091167A2 (en) | 2010-01-22 | 2011-07-28 | The General Hospital Corporation | Lysophosphatidic acid receptor targeting for scleroderma and other fibrotic diseases |
| WO2011159633A1 (en) | 2010-06-15 | 2011-12-22 | Amira Pharmaceuticals, Inc. | Inhalable formulations of lysophosphatdic acid receptor antagonists |
| WO2011159635A1 (en) | 2010-06-15 | 2011-12-22 | Amira Pharmaceuticals, Inc. | Lysophosphatidic acid receptor antagonist for the treatment of dermal conditions |
| US20130253019A1 (en) | 2010-06-15 | 2013-09-26 | John Howard Hutchinson | Lysophosphatidic acid receptor antagonists for the treatment of conditions or diseases of the eye |
| PL2648726T3 (pl) | 2010-12-07 | 2018-10-31 | Amira Pharmaceuticals, Inc. | Policykliczny antagonista lpa1 i jego zastosowania |
| PE20140879A1 (es) | 2010-12-07 | 2014-08-06 | Amira Pharmaceuticals Inc | Antagonistas del receptor de acido lisofosfatidico para el tratamiento de fibrosis |
| US8541587B2 (en) | 2011-04-05 | 2013-09-24 | Amira Pharmaceuticals, Inc. | Lysophosphatidic acid receptor antagonists |
| WO2012138648A1 (en) * | 2011-04-06 | 2012-10-11 | Irm Llc | Compositions and methods for modulating lpa receptors |
| AU2012296662A1 (en) * | 2011-08-15 | 2014-03-27 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
| US20140329871A1 (en) | 2011-12-04 | 2014-11-06 | Angion Biomedica Corp. | Small molecule anti-fibrotic compounds and uses thereof |
| CA2869564A1 (en) | 2012-06-20 | 2013-12-27 | F. Hoffmann-La Roche Ag | N-aryltriazole compounds as lpar antagonists |
| CN104411692A (zh) | 2012-06-20 | 2015-03-11 | 霍夫曼-拉罗奇有限公司 | 作为lpar拮抗剂的n-烷基三唑化合物 |
| KR20150011003A (ko) | 2012-06-20 | 2015-01-29 | 에프. 호프만-라 로슈 아게 | Lpar 길항제로서 치환된 피라졸 화합물 |
| US8986704B2 (en) * | 2012-07-06 | 2015-03-24 | Valneva Austria Gmbh | Mutant fragments of OspA and methods and uses relating thereto |
| RU2649398C2 (ru) | 2012-12-28 | 2018-04-03 | Убе Индастриз, Лтд. | Галогензамещенное гетероциклическое соединение |
| WO2017086430A1 (ja) * | 2015-11-20 | 2017-05-26 | 宇部興産株式会社 | Ｎａｓｈの治療又は予防のための医薬組成物 |
-
2015
- 2015-06-26 CA CA2953472A patent/CA2953472C/en active Active
- 2015-06-26 EP EP15812460.2A patent/EP3162801B1/en active Active
- 2015-06-26 MX MX2016017371A patent/MX370408B/es active IP Right Grant
- 2015-06-26 AU AU2015281021A patent/AU2015281021B9/en active Active
- 2015-06-26 WO PCT/JP2015/068575 patent/WO2015199234A1/ja active Application Filing
- 2015-06-26 KR KR1020177002086A patent/KR102433588B1/ko active IP Right Grant
- 2015-06-26 RU RU2017102513A patent/RU2689315C2/ru active
- 2015-06-26 CN CN201580035089.8A patent/CN106458964B/zh active Active
- 2015-06-26 ES ES15812460T patent/ES2824801T3/es active Active
- 2015-06-26 US US15/321,633 patent/US10023554B2/en active Active
- 2015-06-26 JP JP2016529683A patent/JP6579103B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2689315C2 (ru) | 2019-05-27 |
| EP3162801A4 (en) | 2018-01-24 |
| US10023554B2 (en) | 2018-07-17 |
| CN106458964B (zh) | 2019-11-22 |
| JP6579103B2 (ja) | 2019-09-25 |
| RU2017102513A3 (es) | 2018-12-11 |
| KR102433588B1 (ko) | 2022-08-19 |
| CA2953472C (en) | 2022-08-02 |
| EP3162801A1 (en) | 2017-05-03 |
| CA2953472A1 (en) | 2015-12-30 |
| US20170158663A1 (en) | 2017-06-08 |
| AU2015281021B2 (en) | 2019-03-14 |
| JPWO2015199234A1 (ja) | 2017-04-27 |
| KR20170016988A (ko) | 2017-02-14 |
| WO2015199234A1 (ja) | 2015-12-30 |
| RU2017102513A (ru) | 2018-07-27 |
| BR112016030018A2 (pt) | 2017-08-22 |
| MX2016017371A (es) | 2017-05-01 |
| ES2824801T3 (es) | 2021-05-13 |
| CN106458964A (zh) | 2017-02-22 |
| EP3162801B1 (en) | 2020-07-22 |
| AU2015281021B9 (en) | 2019-03-28 |
| AU2015281021A1 (en) | 2017-01-19 |
| BR112016030018A8 (pt) | 2023-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX370408B (es) | Sal de compuesto heterociclico sustituido con halogeno. | |
| MX2017006266A (es) | Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos. | |
| PH12017500408A1 (en) | Heteroaryl compunds as btk inhibitors and uses thereof | |
| PH12016501813B1 (en) | 1,3-benzodioxole derivative | |
| MX2022009300A (es) | Derivado de quinolina muy puro y metodo para su produccion. | |
| MX2016011992A (es) | Derivados de piperidina-diona. | |
| TW201613911A (en) | Heterocyclic compounds and uses thereof | |
| PH12016502574A1 (en) | Heterocyclic compounds and their use as retinoid-related orphan receptor (ror) gamma-t inhibitors | |
| AU2014375265A1 (en) | Novel pyrazolyl-heteroarylamides as pesticides | |
| MX2018009459A (es) | Derivado de sulfonamida y composicion farmaceutica que contiene el mismo. | |
| PH12019501178A1 (en) | Thiopene derivatives as antiviral agents | |
| MX2016009794A (es) | Derivado de sulfonamida heterociclico y medicina que comprende el mismo. | |
| PH12016501252A1 (en) | Novel tetrahydropyridopyrimidine compound or salt thereof | |
| MX2017003238A (es) | Metodo para preparar 2'-o-fucosil-lactosa. | |
| SG10201809066TA (en) | 5,6-Disubstituted Pyridine-2-Carboxamides and 5,6-Disubstituted Pyrazine-2-Carboxamides as Cannabinoid Receptor Agonists | |
| MX2019013979A (es) | Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol. | |
| MX2020006434A (es) | Nuevos compuestos inhibidores del blanco mecanistico de rapamicina (mtor). | |
| MX2016004393A (es) | Derivados de carboxamida como compuestos pesticidas. | |
| PH12017501404A1 (en) | Diaza-benzofluoranthrene compounds | |
| GEP20186893B (en) | Pyrazines modulators of gpr6 | |
| TN2016000490A1 (en) | Naphthyridinedione derivatives. | |
| MX366678B (es) | Nuevos compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona. | |
| MX2015007309A (es) | Derivado de hidantoina. | |
| MX2020006436A (es) | Compuestos inhibidores del blanco mecanistico de rapamicina (mtor). | |
| TW201613933A (en) | Long acting HIV protease inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |